Stock LVTX LAVA THERAPEUTICS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases LAVA Therapeutics N.V.

Equities

LVTX

NL0015000AG6

Market Closed - Nasdaq
Other stock markets
 01:30:00 02/05/2024 am IST 		5-day change 1st Jan Change
2.97 USD +2.77% Intraday chart for LAVA Therapeutics N.V. +8.39% +87.97%
20/03 LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
20/03 LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
GL
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
AQ
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
GL
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
AQ
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
GL
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
GL
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
GL
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
GL
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
AQ
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
GL
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway
GL
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway
AQ
LAVA Therapeutics N : Consolidated Financial Statements - Form 6-K
PU
LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
GL
LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
AQ
LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
GL
LAVA Therapeutics to Participate in the Jefferies Healthcare Conference
GL
LAVA Announces Annual Meeting of Shareholders
GL
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
GL
LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LVTX Stock
  4. News LAVA Therapeutics N.V.
  5. Press Releases